Consistent with an IL-33–mediated glomerular endothelial immune-pathology in DKD, we observed that both the intracellular and extracellular effects of IL-33 were normalized after treatment with tozorakimab, a high-affinity IL-33–neutralizing immunoglobulin G1 monoclonal antibody developed by AstraZeneca (Figure 3a–e and Supplementary Figure S12).20 This evidence concerns the gene IL33 and diabetic kidney disease.